Phuturdex › Diseases › Systemic lupus erythematosus
Drugs in development · updated 30 October 2026
Systemic lupus erythematosus: drugs in development
As of 30 October 2026 there are 178 active clinical trials (recruiting or ongoing, phases I–III) on 178 drugs for systemic lupus erythematosus. 120 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 120 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AnifrolumabMedi-546, Saphnelo® | III | 6 | NCT05138133 |
| ObinutuzumabGazyva®, Gazyvaro® | III | 4 | NCT04963296 |
| DeucravacitinibBMS-986165, Sotyktu® | III | 3 | NCT07791199 |
| Mycophenolate MofetilMycophenolate, Cellcept | III | 3 | NCT04702256 |
| SirolimusRapamycin, Scomara® | II–III | 3 | NCT07657793 |
| AcetaminophenParacetamol, APAP | III | 2 | NCT04963296 |
| HydroxychloroquineSovuna®, Plaquenil® | III | 2 | NCT05799378 |
| MethotrexateJylamvo®, Reditrex® | III | 2 | NCT06965244 |
| MethylprednisoloneMethylprednisolon, Methylprenisolone | III | 2 | NCT04963296 |
| PrednisonePredinisone, Cortancyl | III | 2 | NCT04702256 |
| UpadacitinibRinvoq Lq®, Rinvoq® | III | 2 | NCT05843643 |
| Dexchlorpheniramine | III | 1 | NCT04702256 |
| DiphenhydramineBenadryl, Benadryl Preservative Free® | III | 1 | NCT04963296 |
| LenalidomideRevlimid, lenalinomide | III | 1 | NCT06965244 |
| NipocalimabM281, Imaavy® | III | 1 | NCT07438496 |
Sorted by most advanced phase and number of active trials. Showing 15 of 58 drugs.
All 178 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Lupus nephritis 64 drugs
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 35 drugs
- Immunoglobulin G4-Related Disease 14 drugs
- IgA glomerulonephritis 48 drugs
- Membranous glomerulonephritis 13 drugs
- Cystinosis 6 drugs
- Myositis 42 drugs
- Diffuse scleroderma 39 drugs
- Chronic renal insufficiency 104 drugs
- Microscopic polyangiitis 6 drugs
- Granulomatosis with polyangiitis 36 drugs
- Churg-Strauss syndrome 7 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Immune System Diseases 54 drugs
- Connective tissue disease 21 drugs
- Autoimmune disease 94 drugs
- Skin disease 34 drugs
- Musculoskeletal disorder 22 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008180 “Lupus Erythematosus, Systemic”. Prevalence: Orphanet.